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Epigenetic alterations represent an important step in the initiation and progression of most human cancers, but it is difficult
to differentiate the early cancer causing alterations from later consequences. Oncogenic viruses can induce transformation via
expression of only a small number of viral genes. Therefore, the mechanisms by which oncogenic viruses cause cancer may provide
clues as to which epigenetic alterations are critical in early carcinogenesis.
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Epigenetics describes the regulation of gene expression and
genomic stability by heritable, but potentially reversible, changes
in DNA methylation and chromatin structure. Significant progress
has been made towards understanding the complementary
functions between the various epigenetic regulators, including
DNA methyltransferases, methylated DNA-binding proteins and
potential DNA demethylases (such as cytosine deaminases).
Histone modifying enzymes interact with other regulators of
chromatin structure, such as ATP-dependent chromatin remodel-
ling complexes and the opposing effects of the polycomb group
(PcG) and trithorax group (TxG) genes (Esteller, 2006). The
mediation of transcriptional repression by microRNAs is also
gaining popularity as an epigenetic mechanism potentially
disrupted in cancer (Esquela-Kerscher and Slack, 2006).
Transcriptionally active genes in a normal cell are marked by
unmethylated promoter CpG islands, histone hyperacetylation
and particular histone modifications, such as H3 lysine 4 (H3K4)
di- and tri-methylation and H3K79 methylation. Transcriptionally
repressed genes are marked by promoter CpG island methylation,
histone hypoacetylation and H3K9 and H3K27 methylation. The
epigenetic landscape of the genome is markedly different in
cancers. A general genome-wide hypomethylation is associated
with repetititve DNA sequences in all cancer cells, alongside
specific promoter hypermethylation of tumour suppressor genes
and hypomethylation of oncogenes (Esteller, 2006). In many
cancer types, the most commonly hypermethylated genes are
involved in DNA repair (hMLH1, MGMT), the cell cycle
(p16INK4a, p15INK4b, p14ARF, SFN), apoptosis (DAPK), cell
adherence (CDH1, CDH13) and detoxification (GSTP1) (Esteller,
2006). In addition to DNA methylation alterations, a number of
critical histone modifications are considered common epigenetic
alterations in cancer, including loss of H4K16 monoacetylation and
H4K20 trimethylation and gains in H3K4 di- and tri-methylation,
H3K79 methylation and H3 and H4 hyperacetylation (Feinberg
et al, 2006).
As with many genetic changes in cancer, it is difficult to
differentiate cause from consequence (Baylin and Ohm, 2006).
Moreover, it is unclear whether genetic or epigenetic changes
occur first and, if epigenetic, whether these involve DNA
methylation or histone modifications. It is very difficult to study
early cancer events in tumours or tumour-derived cell lines,
because they represent end products of transformation and likely
bear little resemblance to the cellular environment of early
carcinogenic events (Baylin and Ohm, 2006). The increasingly
popular idea that cancers originate from disrupted or ‘cancer-
primed’ progenitor cells is supported by the hypothesis that
epigenetic disruption of key genes occurs at the earliest stage of
cancer development (Feinberg et al, 2006). Some of the most
convincing evidence for epigenetic disruption of progenitor cells
derive from the ubiquitous nature of genome-wide hypomethyla-
tion in almost all cancers, common hypermethylation of genes,
such as p16INK4a, in many cancer types (and, occasionally, in
surrounding normal tissues) and ‘germline epimutations’, such as
heightened loss of imprinting (LOI) of insulin-like growth factor 2
in patients at risk for colorectal cancer (Feinberg et al, 2006). Such
observations suggest the exciting prospect that an epigenetic
model could elucidate the early carcinogenic events common to all
cancers.
The identification and isolation of the subpopulation of cancer
progenitor stem cells, most recently in glioblastoma, represents
one potential strategy to elucidate the earliest carcinogenic
changes (Singh et al, 2004). Identification of genetic and epigenetic
differences between cancer progenitor cells and the bulk of other
cancer cells may establish a causal link to their phenotypic
differences. To date, however, the identification of cancer
progenitor stem cells has met with limited success for most cancer
types.
Another strategy to investigate the early events in cancer is to
manipulate and dissect the process by which oncogenic viruses
infect cells and initiate transformation in vitro and in vivo. Viruses
are small and tend to encode only the most important genes
required for their survival, for example genes for viral persistence
and replication, immune regulation and key genes required to
trigger transformation. Oncogenic viruses include retroviruses,
such as human T-cell lymphotrophic viruses 1 and 2 (HTLV1/
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viruses, such as human papilloma virus (HPV), hepatitis B viruses
(HBV), polyomaviruses ((JC virus (JCV), BK virus (BKV) and
simian virus 40 (SV40)) and the gherpesviruses, Epstein–Barr
virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV).
In vitro, oncogenic viruses can induce cellular transformation,
producing cells capable of uncontrolled proliferation and often
tumorigenic in athymic mice. In vivo, viral oncogenesis also
requires additional cellular alterations that enable the transformed
cell to escape host responses, such as the immune system and
apoptosis. Furthermore, viruses exploit epigenetic mechanisms,
such as DNA methylation of viral genes, that would otherwise illicit
an immune response or the increased expression of DNA
methyltransferases that results in increased methylation of cellular
genes (Tsai et al, 2002; Tao and Robertson, 2003). The frequency
of hypermethylation of the cell cycle regulating gene p16INK4a in
HBV-, EBV-, KSHV- and HPV-related tumours suggests the
importance of its inactivation in virally induced cancers (Platt
et al, 2002; Li et al, 2005). This Minireview describes the
interactions between viral proteins and epigenetic regulators that
occur in the host cell to mediate the methylation and histone
alterations required by the virus. The potential involvement of
virally induced epigenetic changes in initiating carcinogenesis is
discussed alongside the viral genes potentially responsible. If
virally induced epigenetic defects mimic the first alterations in
cancer, then these would obviously represent the most effective
targets for cancer drug design.
HOST EPIGENETIC CHANGES OWING TO VIRUSES
AND VIRUS-ASSOCIATED CANCERS
The cause or consequence conundrum in cancer epigenetics is
equally relevant to the epigenetics of viral infection. It is difficult to
differentiate an epigenetic change that is directly due to viral
infection, due to the host antiviral response or due to a subsequent
downstream effect of the transformation process. Do these viruses
happen to infect cancer progenitor cells that are already committed
to cancer development and are, thus, just along for the ride? Or
are cancer progenitor cells more susceptible to viral infection?
Important cancer causing changes may be separated from their
consequences via the identification of direct interactions between
viral proteins and epigenetic regulators (Table 1).
KSHV as an example
Kaposi sarcoma-associated herpesvirus is an oncogenic g-herpes-
virus identified as the causative agent of the endothelial tumour
Kaposi–sarcoma (KS) and associated with the lymphoproliferative
disorders, multicentric Castleman’s disease (MCD) and primary
effusion lymphoma (PEL) (reviewed in Jenner and Boshoff, 2002).
Kaposi sarcoma-associated herpesvirus has both a latent and lytic
phase of its life cycle with a more restricted set of genes expressed
during latency and in the majority of tumour cells. Particularly in
MCD and to a lesser extent in KS and PEL, a small percentage of
cells still express lytic genes and maintain lytic replication, which
may serve to further spread the virus and maintain important
paracrine growth effects of lytic genes such as vGPCR (Jenner and
Boshoff, 2002). Kaposi sarcoma-associated herpesvirus contains
over 80 open reading frames (ORFs), some of which are pirated
from the host genome in order to control proliferation, immune
regulation and cell signalling (Jenner and Boshoff, 2002). The virus
also employs epigenetic mechanisms, for example chromatin
remodelling and demethylation of the lytic switch gene Rta
(ORF50) promoter, to control its entry into the lytic phase and
hyperacetylation of the latent replication origin to control latent
cycle replication (Lu et al, 2006). Given this use of cellular
epigenetic machinery to regulate its own genome during latency





Proteins Epigenetic interactions References
DNA viruses
KSHV KS LANA K Activates DNMT3a (Li et al, 2000; Shamay et al, 2006)
PEL K Interacts with SUV39H1, MeCP2, mSin3, HP1
MCD vIRFs K Binds and inhibits p300/CBP HAT activity.
EBV BL, NPC, HD LMP1 K Activates DNMTs 1,3a,3b (Wang et al, 2000; Tsai et al, 2002;
Knight et al, 2003)
Gastric Cancer EBNA2 K Binds p300 to activate transcription
PTLD EBNA3c K Interacts with HDACs
HPV Papilloma, carcinomas ? K DNMT3b protein is increased by HPV in females only (Patel et al, 1999; Longworth and Laimins, 2004;
Lin et al, 2005; Burgers et al, 2006)
E7 K Binds DNMT1 to increase DNA methyltransferase activity
K Binds HDACs and Nurd ATP-dependent remodelling complex
E6 K Binds and inhibits p300/CBP HAT activity
HBV HCC HBx K Activates DNMT1 (Lee et al, 2005)
SV40 ? Osteosarcoma Large T-Ag K Activates DNMT3b (Soejima et al, 2003)
? Mesothelioma
BKV ? Brain tumours Large T-Ag K Activates DNMT1 (McCabe et al, 2006)
JCV ? Gliomas T-Ag K May induce methylator phenotype in CRC (Goel et al, 2006)
?Medulloblastoma
? CRC
Adenovirus None E1A K Binds DNMT1 to increase DNA methyltransferase activity (Ghosh and Harter, 2003; Turnell et al, 2005;
Burgers et al, 2006; McCabe et al, 2006)
K Binds E2F promoters to demethylate H3K9
K Binds and peturbs p300/CBP HAT activity
RNA viruses
HTLV1/2 ATL Tax K Binds with p300/CBP to repress transcription (Kwok et al, 1996)
ATL¼adult T cell leukemia; BKV¼BK virus; BL¼Burkitts Lymphoma; CRC¼colorectal cancer; EBV¼Epstein–Barr Virus; HBV¼hepatitis B virus; HCC¼hepatocellular
carcinoma; HD¼Hodgkins Disease; HPV¼human papilloma virus; HTLV¼human lymphotrophic virus; JCV¼JC virus; KS¼Kaposi Sarcoma; KSHV¼Kaposi Sarcoma-
associated herpesvirus; MCD¼multicentric Castleman’s Disease; NPC¼Nasopharyngeal Carcinoma; PEL¼primary effusion lymphoma; PTLD¼posttransplant lymphopro-




British Journal of Cancer (2007) 96(2), 183–188 & 2007 Cancer Research UKand lytic replication, the virus may also interact with the host
epigenome as a deliberate mechanism to alter the cellular
environment. There exists clear evidence that KSHV repro-
grammes cellular gene expression in both lymphatic and blood
vessel endothelial cells, although the mechanism of reprogram-
ming remains unclear (Wang et al, 2004). One possibility is that
the virus encodes proteins that are involved in DNA methylation,
histone modifications, chromatin remodelling or microRNA
processing to ensure complete control of cellular gene expression
(Figure 1).
Regarding cellular methylation by KSHV, only p16INK4a
hypermethylation has been identified in the majority of KSHV-
infected PEL cell lines and, potentially, in primary PEL samples
(Platt et al, 2002). This is not surprising, given that p16INK4a is
one of the most commonly hypermethylated genes in nearly all
cancers. This suggests that, in B cells, at least, KSHV is able to
invoke DNA methyltransferase activity and may inactivate other
cellular genes via methylation. A direct link between LANA and the
de novo methyltransferase DNMT3a has been proposed in a study,
that reveals that LANA recruits DNMT3a to the chromatin and
targets repression of approximately 80 cellular genes, some of
which are known targets of epigenetic inactivation in various
cancers (Shamay et al, 2006). In addition, LANA interacts with the
DNA methyl binding protein MeCP2, the mSin3 transcriptional
repression complex and the histone methyltransferase SUV39H1,
thus enabling numerous roles in epigenetic gene regulation (see
Shamay et al (2006) for individual references). Regarding histone
modification of cellular genes, a number of studies have identified
a direct link between the KSHV encoded interferon regulatory
factors (viral interferon regulatory factor (IRF) 1, 2 and 3) and the
histone acetyltransferase complex p300/CBP (Li et al, 2000). The
binding of cellular IRF3 to CBP is thought to be a requirement for
transcriptional activation of the antiviral cytokine interferon-b
(IFN-b). Accordingly, one may assume that KSHV would evolve a
mechanism to disrupt IFN-b activation, which it has by direct
interaction between vIRF1 and either p300 or CBP. In effect, these
interactions inhibit histone acetyltransferase activity and lead to
histone hypoacetylation, altered chromatin structure and reduced
expression of cytokine genes and, presumably, other genes
activated by p300/CBP (Lin et al, 2001). Increased DNA methyla-
tion and decreased histone acetylation are both associated with
gene silencing, which could account for the many genes down-
regulated after KSHV infection.
The importance of epigenetic regulation for gene expression and
the reprogramming of cellular gene expression during viral
transformation suggests that other viral genes (latent or lytic)
may also be involved in epigenetic control of gene expression.












Figure 1 Viral control of the host epigenome. Epigenetic control of gene expression occurs at four different levels starting with chromatin packaging into
higher order chromatin structures controlled by ATP-dependent chromatin remodelling complexes (ATP-DRs), PcG and TxG genes. DNA is wrapped
around nucleosomes that are assembled from dimers of the histones H2A, H2B, H3 and H4, all of which contain tails that can be either acetylated (HATs)
and demethylated (HDMTs) during active transcription or deactylated (HDACs) and highly methylated (HMTs) during repressed transcription. At the
nucleotide level, epigenetic control via DNA methylation is mediated by the DNA methylating enzymes (DNMTs), methyl-DNA-binding proteins (e.g.
MeCBPs) and cytosine deaminases that could act as demethylating enzymes. Finally, transcriptional repression is also mediated by microRNAs. Oncogenic
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investigating the epigenetic functions of the cellular genes, one
may also infer interactions or functions related to epigenetic
control by the viral genes. Using this strategy, a number of viral
genes appear likely epigenetic regulators, including viral inter-
leukin-6 (IL-6), viral G-protein coupled receptor and the 12 KSHV
microRNAs (Table 2). Speculation on viral gene function based on
the functions of cellular homologues can provide interesting leads
and has proved correct for the viral IRFs, but there exist cases
wherein the viral gene does not function in the manner of its
cellular homologue. For instance, vIL-6 does not bind to the
cellular IL-6 receptor. Rather, it binds only to the gp130 receptor.
At present, the potential cellular or viral targets of the KSHV
microRNAs exist only as in silico predictions, among which are the
cytokine signalling regulator SOCS3, DNA repair gene RAD21, the
tumour necrosis factor-a (TNF-a) and the kinase MAP3K8, which
is also involved in production of TNF-a (Cai et al, 2005). Whether
or not there are cellular homologues of the viral microRNAs has
yet to be explored. Accordingly, whether or not the viral genes
described here are actually involved in epigenetic regulation must
be investigated experimentally.
Other oncogenic viruses
Increased DNA methylation activity and decreased histone
acetylation activity are not unique properties of KSHV, as other
oncogenic viruses also share these properties (Table 1). The related
g-herpesvirus, EBV, activates DNA methyltransferase activity by
increasing the expression of the maintenance methyltransferase
DNMT1 and both de novo methyltransferases, DNMT3a and
DNMT3b (Tsai et al, 2002). The LMP 1 protein is one of the key
oncogenic viral proteins of EBV and it is not surprising that this is
the protein that alters the DNA methyltransferase activity. The
hepatitis B virus HBx protein, BK polyoma virus T-antigen and the
adenovirus oncogene E1A all increase the activity of DNMT1 alone
(Lee et al, 2005; McCabe et al, 2006). In both EBV and HBV-related
epithelial cancers, this results in increased methylation and
suppression of E-cadherin, thereby increasing cell migration (Tsai
et al, 2002; Lee et al, 2005). The HPV acts similar to KSHV in that it
appears to increase the de novo methyltransferase, DNMT3b
protein, in nonsmoking lung cancers, curiously only in females
(Lin et al, 2005). Although no HPV protein has been identified as
the culprit for this increase in DNMT3b, a recent study has now
shown that HPV E7-protein increases DNA methyltransferase
enzymatic activity by directly interacting with DNMT1 (Burgers
et al, 2006). The link between JCV and increased DNA methylation
is more speculative with an association between the JCV T-antigen
expression and the methylator phenotype in colorectal cancer
(Goel et al, 2006). The simian SV40 virus increases DNA
methylation by upregulation of DNMT3b via the large T antigen
(Soejima et al, 2003). The association between SV40 and human
cancers is still contentious; however, this does provide an
interesting insight into the possibility that activation of methyla-
tion may be conserved among other mammalian viruses. Although
methylation of p16INK4a occurs in hepatocellular carcinoma
associated with the HCV, no direct interactions have yet been
identified.
The ability to alter histone modifications and chromatin
structure is also common to many oncogenic viruses including
EBV, HPV, adenovirus and HTLV1. The EBV nuclear antigens
EBNA 2 and 3c alter histone acetylation by interacting with the
p300/CBP complex or with histone deacetylase (HDAC), respec-
tively (Wang et al, 2000; Knight et al, 2003). Human papilloma
virus oncoprotein E6 binds and inhibits the histone acetyltransfer-
ase activity of the p300/CBP complex similar to KSHV (Patel et al,
1999). This transcriptional repressive activity by HPV is further
supported by E7 protein interaction with HDAC1 and the Nurd
ATP-dependent chromatin remodelling complex that are also
involved in repression (Longworth and Laimins, 2004). The
adenovirus transforming protein E1A also interacts with the
p300/CBP transcriptional complex to peturb or alter the normal
functioning during the cell cycle (Turnell et al, 2005). This has
been described as one of the key events in the induction of E1A-
induced cellular transformation. Finally, the retrovirus HTLV1 Tax
protein also interacts with the p300/CBP complex to mediate
transcriptional repression (Kwok et al, 1996).
It is interesting to note that the EBV proteins that interact with
epigenetic regulators (EBNA2, EBNA3c and LMP1) are all latent
genes and are not typically expressed in Burkitt’s lymphoma,
gastric cancer and most nasopharyngeal carcinomas. This may lead
to the conclusion that the role of virus-induced host epigenetic
changes may be limited in these particular cancers. However, it
cannot be ruled out that the initial cancer precursor cells may have
harboured the virus in a latent phase in which the host epigenome
could be altered. Epigenetic fingerprints such as DNA methylation
and histone modifications are mitotically heritable and, thus, even
if the progeny cancer cell no longer expresses these latent genes, the
epigenetic history of the cell may remain. It is also interesting to
observe that the proteins that interact with epigenetic mechanisms,
LMP1, LANA, E6 and E7, large T antigen, E1A and Tax, are often
described as the viral ‘oncoproteins’ as they are often either
oncogenic on their own or essential components of viral
transformation. This typically leads to the conclusion that the
functions of these proteins, in this case the epigenetic functions, are
indeed essential for viral-induced transformation.
Returning to the hypothesis that viral-induced epigenetic
changes might mimic the early events in cancers, we can observe
from these studies described that disruption or alteration of




Epigenetic functions of cellular
homologues References
K2 (vIL6) IL6 B-cell growth factor, angiogenesis,
hematopoiesis
K IL6 regulates expression of DNMT1 (Croonquist and Van Ness, 2005;
Hodge et al, 2005; Peng et al, 2005)
K IL6 supports the maintenance of p53
promoter methylation
K IL6 supports methylation of the
RAD23B DNA repair gene
K IL6 induces polycomb group gene EZH2
ORF74 (vGPCR) GPCR/ IL-8R Angiogenesis; transformation K GPCR signaling regulates histone
acetylation and gene transcription
(Kang et al, 2005)
KSHV miRNAs
(mirK1-mirK12)
None yet identified Transcriptional repression. Some
predicted cellular targets include TNF,
SOCS3, RAD21 and MAP3K8
K miRNAs (Oncomirs) such as the let-7
family regulate expression of oncogenes
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oncogenic viruses, which suggests that it may be one of the critical
early events in viral-induced carcinogenesis. Further evidence for
an early involvement of p300/CBP in nonviral cancers can be
observed in the increased predisposition to childhood malignan-
cies in Rubinstein–Taybi syndrome, which is characterised by
germline mutation of CBP as well as numerous somatic mutations
in colorectal, breast and gastric carcinomas (Iyer et al, 2004). This
suggests that abrogation or peturbation of the histone acetyl-
transferase activity of p300/CBP may also be one of the critical
early events in all cancers. Similarly, an increase in DNA
methyltransferase activity might also be a crucial early event.
Disruption of either the maintenance methylatransferase, DNMT1,
or the de novo methyltransferases, DNMT3a or 3b, suggests that
each oncogenic virus may have evolved different routes to the
same goals (methylation of key tumour suppressor genes) or
perhaps that different viruses require inactivation of different
genes via different methyltransferases. Interestingly, ranid herpes-
virus 1 (RaHV-1), which is the aeitiological agent of kidney cancers
in the North American leopard frog Rana pipiens encodes its own
DNA (cytosine-5) methyltransferase, further suggesting that
alteration of methylation in the host genome is a highly conserved
function in oncogenic viruses (Davison et al, 1999). Again, in
nonviral cancers, this is also a common finding with an overall
increase in DNA methyltransferase activity in many tumours
compared with normal tissues (Esteller, 2006). Both of these
activities, disruption of histone acetylation and increased DNA
methylation, are related to repression of transcription, which
provides support for the idea that the critical early carcinogenic
events begin with the inactivation of tumour-suppressor genes
(Feinberg et al, 2006). A more complete understanding of the
interactions between viral proteins and epigenetic regulators may
be a very important step in understanding the earliest alterations
in cancer. In addition, identification of the particular changes
induced by viruses might provide novel, and more effective, targets
for cancer therapies.
CONCLUSIONS
It is apparent from current knowledge that KSHV and other
oncogenic viruses increase activity of DNA methyltransferases and
can decrease p300/CBP-mediated histone acetylation, which are
both likely requirements for the inactivation of tumour-suppressor
genes. The fact that both of these events also occur in many other
nonviral cancers suggests that these may indeed be some of the
earliest alterations in carcinogenesis. Identification of cancer
progenitor cells with increased DNA methyltransferase activity
and abrogated p300/CBP histone acetyltransferase activity would
further support this hypothesis. Furthermore, there exists the
potential for other viral genes in epigenetic control, as proposed in
this review for KSHV, and thus there is scope for identification of
novel epigenetic alterations as early carcinogenic events.
There is gathering momentum for the use of epigenetic related
therapies, such as HDAC inhibitors, for example suberoylanilide
hydroxamic acid (SAHA), which is currently in Phase III trials and
has shown reasonable efficacy in haematological and solid
tumours. At present, five trials are investigating the use of HDAC
inhibitor valproic acid (VPA) in Kaposi sarcoma, EBV-related
nasopharyngeal carcinoma and non-Hodgkin’s lymphoma, as well
as in HIV-infected patients (http://clinicaltrials.gov/). Some
circumspection is required, however, because histone deacetylase
inhibitors, including valproate, may induce lytic replication, as has
been shown for KSHV and EBV (Klass et al, 2005; Feng and
Kenney, 2006; Lu et al, 2006). For an effective drug, it would be
preferable to induce lytic replication and induce apoptosis without
increasing the viral load. A recent study has shown that valproate
can induce entry into the lytic cycle in KSHV-infected PEL cells
and can significantly increase production of the virus, leading
to cell death by apoptosis (Klass et al, 2005). With the addition of
ganciclovir and PFA, viral DNA replication was blocked without
blocking the lytic cascade and apoptosis, which advocates the use
of HDAC inhibitors in combination therapies rather than as single
agents in virus-associated cancers. Other HDAC inhibitors
(depsipeptide, SAHA, MS-275 and trichostatin A) have also
been tested in PEL cells with minimal (3–14%) reactivation
(Niedermeier et al, 2006). Given our present understanding of the
epigenetic control required by oncogenic viruses in the transfor-
mation process, the use of HDAC inhibitors, or other epigeneti-
cally targeted therapies, is warranted in virus associated tumours.
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